Breast Cancer

FDA Approves Olaparib for Germline BRCA-Mutated Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) granted regular approval to olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who have been treated with chemotherapy in either the neoadjuvant, adjuvant, or metastatic setting.

Colorectal Cancer

Adding First-Line Radiotherapy to Chemotherapy for Liver Metastases From Colorectal Cancer

A meta-analysis of three randomized trials (FOXFIRE, SIRFLOX, and FOXFIRE-Global) indicates no overall survival benefit of adding first-line selective internal radiotherapy to chemotherapy in patients with liver metastases from colorectal cancer. The findings were reported by Wasan and colleagues in The Lancet Oncology. Ricky Sharma, PhD, of the University College London Cancer Institute, is the corresponding author of The Lancet Oncologyarticle.

Lymphoma

Updated Follow-up of ZUMA-1 Confirms Benefit of CAR T-Cell Therapy in Aggressive B-Cell Lymphoma

Positive data about chimeric antigen receptor (CAR) T-cell therapy in lymphoma continue to accrue. Long-term follow-up of the pivotal ZUMA-1 trial shows that patients with refractory diffuse large B-cell lymphoma (DLBCL) continue to have durable responses to the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (Yescarta) after more than 1 year.


Advertisement

More Top Stories

Palliative Care

Thomas J. Smith, MD, on Palliative Care and Outpatient Treatment: Expert Perspective

Supportive Care
Solid Tumors
Lung Cancer

Providing a Safe Haven for Patients With Advanced Lung Cancer

In 1996, Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center (MSK) in New York, decided to launch the cancer center’s Lung Cancer Survivorship Program after she had a startling encounter with a patient. “The woman said to me, ‘Would...

Advertisement

FDA Approves Olaparib for Germline BRCA-Mutated Metastatic Breast Cancer

Today, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who have been...

Issues in Oncology
Palliative Care

Sandip Patel, MD, on Immunotherapy: New Developments and Toxicity Challenges

Gynecologic Cancers
Hepatobiliary Cancer
Gastroesophageal Cancer
Leukemia

Reports From the Journal of Clinical Oncology

Immunotherapy in PD-L1–Positive Advanced Cervical Cancer Pembrolizumab (Keytruda) treatment was active in patients with programmed cell death ligand 1 (PD-L1)–positive advanced cervical cancer enrolled in the phase Ib KEYNOTE-028 trial. The findings were reported by Jean-Sebastien Frenel, MD, of...

Mohamad Cherry, MD, Joins Atlantic Hematology Oncology

AWARD-WINNING physician-researcher Mohamad Cherry, MD, has joined Atlantic Hematology Oncology, part of Atlantic Health System’s Atlantic Medical Group at the Carol G. Simon Cancer Center. Dr. Cherry, who is board certified in internal medicine, hematology, and medical oncology, joins Atlantic...

Study Finds Desmoplastic Melanoma Highly Responsive to PD-1/PD-L1 Blockade

Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients. Treatment is difficult, as these tumors are often resistant to chemotherapy and lack actionable mutations commonly found in other types of...

Hematologic Malignancies
Issues in Oncology
Cost of Care

Alok A. Khorana, MD, on The Costs of VTE in Cancer Patients: Expert Perspective

Lymphoma

PI3K Inhibition With Copanlisib in Relapsed or Refractory Indolent Lymphoma

AS REPORTED in the Journal of Clinical Oncology by Martin Dreyling, MD, PhD, of University Hospital, Ludwig Maximilians University of Munich, and colleagues, the phase II CHRONOS-1 trial has shown a high response rate and durable responses with the phosphatidylinositol 3-kinase (PI3K) inhibitor...

Advertisement

Out-of-Pocket Costs and Prescription Abandonment of Novel Oral Anticancer Agents

In a retrospective claims-based study reported in the Journal of Clinical Oncology, Doshi et al found that higher out-of-pocket costs were associated with increased rates of prescription abandonment for novel oral anticancer agents. Study Details The study involved data on 38,111 patients from...